Search

Prasanth Manohar I have completed my Ph.D. at Vellore Institute of Technology, Vellore, India. My research project deals with the characterization of bacteriophages infecting E. coli, K. pneumoniae and Enterobacter species. I have expertise

The World Health Organization wants to better understand the current pre-clinical antibacterial R&D landscape! Companies, institutions and individuals doing pre-clinical work targeting any of the WHO Priority Pathogens, TB and/or C. diffici

A new NIH funding announcement involving phages: exploratory/developmental research into microbial-based cancer therapy ("Bugs as Drugs"). Excerpt: "Utilizing bacteria, archaebacteria, bacteriophages and other non-virus microorganisms, this

The University of Pittsburgh has established the Roger W. Hendrix Fund to honor a giant in the phage field who was lost too soon. Please consider contributing to this endowed fund to support and encourage future generations of scientists an

Dr. Ellie Jameson's lab at Warwick University is now offering reproducible, standardized tests to investigate phages as targeted bactericidal agents. Also available: optimized phage methods to investigate interactions with other antimicrobi

Dr. Benjamin Chan of Yale University continues his treatment of patients in need with phages. Most recently, his phages were administered to a 26-year-old woman named Ella Balasa from Richmond, Virginia, who traveled to Yale for treatment.

The Perfect Predator came out this week! Expect a lot of new mainstream press for phages over the coming weeks/months! This week has already brought coverage from Wired and People, and tomorrow morning at 9 AM, Steffanie Strathdee and Tom P

Check out our new paper on sourcing phages for compassionate use, which was published in the journal Microbiology Australia last week!

Michael Van Delle University of Toronto researchers have developed a novel phage susceptibility testing platform. To understand the need for such a solution, Adventus Research + Consulting is reaching out to phage community experts, stakeho

Michael Van Delle University of Toronto researchers have developed a novel phage susceptibility testing platform. To understand the need for such a solution, Adventus Research + Consulting is reaching out to phage community experts, stakeho

Check out this extremely informative Twitter thread by Simon Roux, which breaks down his new preprint on the pervasiveness of Inoviruses. Detect Inoviruses in your own sequence data with this tool (Github). We want to encourage more scienti

Carol E. Zhou and colleagues report a new phage annotation pipeline called multiPhATE. Preprint and Github.

A new virome twin study! J. Leonardo Moreno-Gallego and colleagues show that virome and microbiome diversity correlate, and in contrast to a prior study, adult twins DO have more similar viromes than unrelated individuals. They suggest that

Rob Lavigne at KU Leuven is seeking comments on his new preprint on patents related to phage use in agriculture. Comment under the paper on BioRxiv, or tweet @RobLavigne1!

This commentary by Jens H. Kuhn and colleagues may convince you to care more about the need for cataloguing viral genomes.

Great news for BiomX, a company developing custom phage therapies to treat microbiome-based diseases, which just raised $32 million in series B financing!

Cell Host & Microbe just released a special issue devoted to phages!. This includes four free featured reviews, one of which is this article by Kaitlyn Kortright, Benjamin Chan, Jonathan Koff and Paul Turner of Yale University, where they d

Fernando L. Gordillo Altamirano and Jeremy Barr from Monash University in Melbourne, Australia have published a new review: Phage Therapy in the Post-Antibiotic Era. Their paper includes a nice timeline of phage therapy history and a beauti

Stephen Wandro and colleagues at the University of California, Irvine have published a new paper on Enterococcus faecium phage evolution. His experiments, which he presented at Kisaco Research's North American Microbiome Congress last week,

Intralytix's phage clinical trial (treating E. coli in IBD patients) at Mt. Sinai hospital has begun! Here's a video interview with two Mt. Sinai doctors involved in the trial